Cell ther­a­py start­up A2 Bio­ther­a­peu­tics nets $80M Se­ries C

A2 Bio­ther­a­peu­tics has raised $80 mil­lion to run three ex­per­i­men­tal CAR-T pro­grams for sol­id tu­mor can­cers.

The biotech is de­vel­op­ing what it calls log­ic-gat­ed cell …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER